Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 589

1.

Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib.

Lachenmayer A, Alsinet C, Savic R, Cabellos L, Toffanin S, Hoshida Y, Villanueva A, Minguez B, Newell P, Tsai HW, Barretina J, Thung S, Ward SC, Bruix J, Mazzaferro V, Schwartz M, Friedman SL, Llovet JM.

Clin Cancer Res. 2012 Sep 15;18(18):4997-5007. Epub 2012 Jul 18.

2.

Synergistic inhibition of HCC and liver cancer stem cell proliferation by targeting RAS/RAF/MAPK and WNT/β-catenin pathways.

Galuppo R, Maynard E, Shah M, Daily MF, Chen C, Spear BT, Gedaly R.

Anticancer Res. 2014 Apr;34(4):1709-13.

PMID:
24692700
3.

Sorafenib sensitizes hepatocellular carcinoma cell to cisplatin via suppression of Wnt/β-catenin signaling.

Wei Y, Shen N, Wang Z, Yang G, Yi B, Yang N, Qiu Y, Lu J.

Mol Cell Biochem. 2013 Sep;381(1-2):139-44. doi: 10.1007/s11010-013-1695-6. Epub 2013 Jun 12.

PMID:
23756716
4.

PROX1 promotes hepatocellular carcinoma proliferation and sorafenib resistance by enhancing β-catenin expression and nuclear translocation.

Liu Y, Ye X, Zhang JB, Ouyang H, Shen Z, Wu Y, Wang W, Wu J, Tao S, Yang X, Qiao K, Zhang J, Liu J, Fu Q, Xie Y.

Oncogene. 2015 Oct 29;34(44):5524-35. doi: 10.1038/onc.2015.7. Epub 2015 Feb 16.

PMID:
25684142
5.

Synergistic effects of β-catenin inhibitors and sorafenib in hepatoma cells.

Muche S, Kirschnick M, Schwarz M, Braeuning A.

Anticancer Res. 2014 Sep;34(9):4677-83.

PMID:
25202044
6.

Integrative analysis of aberrant Wnt signaling in hepatitis B virus-related hepatocellular carcinoma.

Ding SL, Yang ZW, Wang J, Zhang XL, Chen XM, Lu FM.

World J Gastroenterol. 2015 May 28;21(20):6317-28. doi: 10.3748/wjg.v21.i20.6317. Review.

7.

1118-20, an indazole diarylurea compound, inhibits hepatocellular carcinoma HepG2 proliferation and tumour angiogenesis involving Wnt/β-catenin pathway and receptor tyrosine kinases.

Lu YY, Wang JJ, Zhang XK, Li WB, Guo XL.

J Pharm Pharmacol. 2015 Oct;67(10):1393-405. doi: 10.1111/jphp.12440. Epub 2015 Jun 16.

PMID:
26076716
8.

Tankyrase inhibitors attenuate WNT/β-catenin signaling and inhibit growth of hepatocellular carcinoma cells.

Ma L, Wang X, Jia T, Wei W, Chua MS, So S.

Oncotarget. 2015 Sep 22;6(28):25390-401. doi: 10.18632/oncotarget.4455.

9.

ALDH3A1 is overexpressed in a subset of hepatocellular carcinoma characterised by activation of the Wnt/ß-catenin pathway.

Calderaro J, Nault JC, Bioulac-Sage P, Laurent A, Blanc JF, Decaens T, Zucman-Rossi J.

Virchows Arch. 2014 Jan;464(1):53-60. doi: 10.1007/s00428-013-1515-0. Epub 2013 Nov 26.

PMID:
24276407
10.

MiR-214 targets β-catenin pathway to suppress invasion, stem-like traits and recurrence of human hepatocellular carcinoma.

Xia H, Ooi LL, Hui KM.

PLoS One. 2012;7(9):e44206. doi: 10.1371/journal.pone.0044206. Epub 2012 Sep 4. Erratum in: PLoS One. 2012;7(9). doi:10.1371/annotation/1be2a62e-45a1-4c13-9a8d-f265005a21e0.

11.

Cyr61/CCN1 is regulated by Wnt/β-catenin signaling and plays an important role in the progression of hepatocellular carcinoma.

Li ZQ, Ding W, Sun SJ, Li J, Pan J, Zhao C, Wu WR, Si WK.

PLoS One. 2012;7(4):e35754. doi: 10.1371/journal.pone.0035754. Epub 2012 Apr 23.

12.

Dickkopf 4 (DKK4) acts on Wnt/β-catenin pathway by influencing β-catenin in hepatocellular carcinoma.

Fatima S, Lee NP, Tsang FH, Kolligs FT, Ng IO, Poon RT, Fan ST, Luk JM.

Oncogene. 2012 Sep 20;31(38):4233-44. doi: 10.1038/onc.2011.580. Epub 2012 Jan 16.

PMID:
22249261
13.

EZH2-mediated concordant repression of Wnt antagonists promotes β-catenin-dependent hepatocarcinogenesis.

Cheng AS, Lau SS, Chen Y, Kondo Y, Li MS, Feng H, Ching AK, Cheung KF, Wong HK, Tong JH, Jin H, Choy KW, Yu J, To KF, Wong N, Huang TH, Sung JJ.

Cancer Res. 2011 Jun 1;71(11):4028-39. doi: 10.1158/0008-5472.CAN-10-3342. Epub 2011 Apr 21.

14.

Canonical Wnt signaling is antagonized by noncanonical Wnt5a in hepatocellular carcinoma cells.

Yuzugullu H, Benhaj K, Ozturk N, Senturk S, Celik E, Toylu A, Tasdemir N, Yilmaz M, Erdal E, Akcali KC, Atabey N, Ozturk M.

Mol Cancer. 2009 Oct 22;8:90. doi: 10.1186/1476-4598-8-90.

15.

Sorafenib-mediated targeting of the AAA⁺ ATPase p97/VCP leads to disruption of the secretory pathway, endoplasmic reticulum stress, and hepatocellular cancer cell death.

Yi P, Higa A, Taouji S, Bexiga MG, Marza E, Arma D, Castain C, Le Bail B, Simpson JC, Rosenbaum J, Balabaud C, Bioulac-Sage P, Blanc JF, Chevet E.

Mol Cancer Ther. 2012 Dec;11(12):2610-20. doi: 10.1158/1535-7163.MCT-12-0516. Epub 2012 Oct 5.

16.

BCRP/ABCG2 inhibition sensitizes hepatocellular carcinoma cells to sorafenib.

Huang WC, Hsieh YL, Hung CM, Chien PH, Chien YF, Chen LC, Tu CY, Chen CH, Hsu SC, Lin YM, Chen YJ.

PLoS One. 2013 Dec 31;8(12):e83627. doi: 10.1371/journal.pone.0083627. eCollection 2013.

17.

Proliferation and migration mediated by Dkk-1/Wnt/beta-catenin cascade in a model of hepatocellular carcinoma cells.

Qin X, Zhang H, Zhou X, Wang C, Zhang H, Zhang X, Ye L.

Transl Res. 2007 Nov;150(5):281-94. Epub 2007 Jul 18.

PMID:
17964517
18.

Radiosensitivity enhancement of human hepatocellular carcinoma cell line SMMC-7721 by sorafenib through the MEK/ERK signal pathway.

Dai XF, Ding J, Zhang RG, Ren JH, Ma CM, Wu G.

Int J Radiat Biol. 2013 Sep;89(9):724-31. doi: 10.3109/09553002.2013.791405. Epub 2013 May 31.

PMID:
23682582
19.

Upregulation of HIF-2α induced by sorafenib contributes to the resistance by activating the TGF-α/EGFR pathway in hepatocellular carcinoma cells.

Zhao D, Zhai B, He C, Tan G, Jiang X, Pan S, Dong X, Wei Z, Ma L, Qiao H, Jiang H, Sun X.

Cell Signal. 2014 May;26(5):1030-9. doi: 10.1016/j.cellsig.2014.01.026. Epub 2014 Jan 29.

PMID:
24486412
20.

NDRG1 promotes growth of hepatocellular carcinoma cells by directly interacting with GSK-3β and Nur77 to prevent β-catenin degradation.

Lu WJ, Chua MS, Wei W, So SK.

Oncotarget. 2015 Oct 6;6(30):29847-59. doi: 10.18632/oncotarget.4913.

Items per page

Supplemental Content

Write to the Help Desk